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APOBEC3-mediated restriction of 
RNA virus replication
Aleksandra Milewska1,2, Eveline Kindler3,4, Philip Vkovski  3,4,5, Slawomir Zeglen6,7,  
Marek Ochman8, Volker Thiel3,4, Zenon Rajfur9 & Krzysztof Pyrc  1,2
APOBEC3 family members are cytidine deaminases with roles in intrinsic responses to infection by 
retroviruses and retrotransposons, and in the control of other DNA viruses, such as herpesviruses, 
parvoviruses and hepatitis B virus. Although effects of APOBEC3 members on viral DNA have been 
demonstrated, it is not known whether they edit RNA genomes through cytidine deamination. Here, 
we investigated APOBEC3-mediated restriction of Coronaviridae. In experiments in vitro, three 
human APOBEC3 proteins (A3C, A3F and A3H) inhibited HCoV-NL63 infection and limited production 
of progeny virus, but did not cause hypermutation of the coronaviral genome. APOBEC3-mediated 
restriction was partially dependent on enzyme activity, and was reduced by the use of enzymatically 
inactive APOBEC3. Moreover, APOBEC3 proteins bound to the coronaviral nucleoprotein, and this 
interaction also affected viral replication. Although the precise molecular mechanism of deaminase-
dependent inhibition of coronavirus replication remains elusive, our results further our understanding of 
APOBEC-mediated restriction of RNA virus infections.
Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like type 3 (APOBEC3) proteins are Zn2+ - 
dependent cytidine deaminases that belong to the APOBEC superfamily. APOBEC3 enzymes are considered 
to be part of the intrinsic defense system in eukaryotic cells, and can inhibit replication of some viruses and 
restrict mobile genetic elements. All APOBEC3 proteins share a cytidine-deaminase domain, which is identifi-
able by the primary amino acid motif His-Xaa-Glu-Xaa23–28-Pro-Cys-Xaa2–4-Cys, in which Zn2+ is coordinated. 
Deamination of cytidine results in its conversion to uridine. During this process, the ammonium group on C4 
of cytidine undergoes nucleophilic attack by an activated water molecule and the APOBEC3 glutamate residue.
A single copy of a gene encoding APOBEC3 is found in the genomes of rodents, cats, pigs and sheeps, with 
two genes in the genomes of cows, three the genomes of dogs and horses and seven genes in the human genome, 
encoding A3A, A3B, A3C, A3D, A3F, A3G and A3H1. The mechanisms and selective pressures that led to the 
APOBEC3 gene expansion in humans are unclear, but it is believed that all the genes originated from duplication 
of a single-copy primordial APOBEC3 gene. This multiplication may have provided protection from genomic 
instability caused by human endogenous retroviruses and retrotransposons2.
The best-studied protein within the human APOBEC3 family is A3G. Its function as an antiviral factor was 
discovered in 2002 through cDNA-transfer experiments that were designed to identify a cellular suppressor of an 
HIV-1 accessory protein, the virion infectivity factor (Vif). The primary antiretroviral activity of A3G requires its 
encapsidation into HIV-1 particles, and involves cytidine deamination of the reverse-transcribed first viral DNA 
strand, with mutations becoming fixed as G to A changes upon second-strand synthesis. Mutational frequencies 
can exceed 10% of all G residues (hypermutation), and may result in inhibition of viral replication. This activity 
is blocked by Vif protein, which specifically binds to and ubiquitinates A3G, directing it for degradation in the 
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proteasome1,3,4. Other APOBEC3 proteins have been found to affect a wide variety of viruses, including other ret-
roviruses (e.g., simian immunodeficiency virus (SIV), equine infectious anemia virus (EIAV), murine leukemia 
virus (MLV), foamy viruses), and DNA viruses (e.g., hepatitis B virus, parvovirus)5–14. As well as the inhibition 
of viral replication by hypermutation, APOBEC3-induced mutations also cause degradation of viral genomic 
material, mediated by cellular DNA-repair mechanisms15.
The RNA-editing capability of APOBEC3 proteins was identified in 200416, since when extensive mutational 
activity of A3A on RNA transcripts in monocytes and macrophages has been demonstrated17. Our current under-
standing of the APOBEC3 proteins suggests that they may also constitute an innate defense system against RNA 
viruses. For example, A3G known to be involved in restriction of three RNA pathogens (the mumps, measles and 
respiratory syncytial viruses), but whether this effect is associated with cytidine deamination is not yet known18.
Members of the family Coronaviridae are positive-strand RNA viruses with large genomes, ranging in size 
from 27 to 32 kb. Six human coronaviruses (HCoVs) have been identified, four of which (HCoV-OC43, HCoV-
229E, HCoV-NL63 and HCoV-HKU1) circulate continuously in human populations. These four viruses cause 
the common cold in otherwise healthy adults, and may cause more severe symptoms in young, elderly and immu-
nocompromised individuals19–22. Other coronaviruses that infect humans can cause severe and life-threatening 
diseases. In 2002, severe acute respiratory syndrome coronavirus (SARS-CoV) emerged and affected ~8,000 
individuals, causing ~800 deaths23,24. Middle East respiratory syndrome coronavirus (MERS-CoV) is the most 
recently identified coronaviruse that infects humans. MERS-CoV was isolated in 2012 and is associated with 
severe pneumonia and renal failure, with a mortality rate of ~30%25,26.
HCoV-NL63 was identified in 2004 and is distributed worldwide, with highest prevalence during winter and 
early spring in temperate climate27. HCoV-NL63 accounts for a considerable number of hospitalisations among 
children <18 years of age, the elderly and immunocompromised individuals19. A notable characteristics of coro-
naviruses is that their genomes are highly U/A-rich and C/G-poor. For example, HCoV-NL63 has 39% U and 27% 
A content, with only 14% C and 20%, G nucleotides28. The explanations for this bias is not yet known28,29. One 
possibility is that, over an evolutionary timescale, genomes of coronaviruses might have been shaped by cytidine 
deamination. Our aim, therefore, was to determine whether APOBEC3 proteins might be responsible for this 
modification. Our results demonstrate that three of the APOBEC3 proteins (A3C, A3F and A3H) can inhibit 
coronaviral infection in vitro.
Results
APOBEC3-family gene expression is upregulated in HCoV-NL63-infected cells. Modulation of 
human APOBEC3-family transcript levels in human airway epithelium (HAE) cultures during coronavirus infec-
tion was evaluated by quantitative RT-PCR (qRT-PCR) with primers and standards developed in our lab. The 
level of each APOBEC3 mRNA was analysed in fully differentiated cells from healthy adults, and a high level of 
expression was observed for six out of seven human APOBEC3 genes (Fig. 1a). The same six genes (APOBEC3A, 
APOBEC3C, APOBEC3D, APOBEC3F, APOBEC3G and APOBEC3H) were expressed during HCoV-NL63 infec-
tion, and these genes were analysed in subsequent experiments.
HAE cultures were infected with HCoV-NL63 and cultured for 5 days at 32 °C. As a control, HAE cultures were 
infected with influenza A H3N2 virus, which induces considerable upregulation of APOBEC3G30. RT-qPCR anal-
ysis of total RNA extracted from infected cells revealed upregulation of APOBEC3A, APOBEC3C, APOBEC3D 
and APOBEC3F transcripts in HCoV-NL63-infected cells relative to mock-infected cells, with an almost 
100-fold increase in APOBEC3A expression (Fig. 1b). As anticipated, APOBEC3G was upregulated in the 
influenza-infected cells, and APOBEC3H expression also increased (Fig. 1c).
Expression of APOBEC3 proteins in cultured cells. Plasmids encoding individual APOBEC3 proteins 
were prepared and transfected into 293T cells, which were cultured and analysed for protein expression by west-
ern blotting (Fig. 2a, Supplementary Figure 1). For expression in the naturally permissive LLC-Mk2 cell line, in 
which the DNA transfection efficiency is very low (data not shown), mRNA transcripts encoding APOBEC3 pro-
teins or green fluorescent protein (GFP) were prepared by in vitro transcription. Transfection of LLC-Mk2 cells 
was efficient, reaching ~80% for the control GFP mRNA (Fig. 2b). Expression of HA-tagged APOBEC3 proteins 
in mRNA transfected LLC-Mk2 cells, measured by flow cytometry, was similar for all proteins (Fig. 2c).
Human APOBEC3 proteins A3C, A3F and A3H inhibit HCoV-NL63 replication. mRNA-transfected 
LLC-Mk2 cells were infected with HCoV-NL63 and cultured for 5 days at 32 °C. No cytopathic effect (CPE) 
was observed in cells expressing A3C, A3F and A3H proteins, but CPE was observed in untransfected or 
GFP-transfected cells, and in cells expressing A3A, A3DE and A3G (Fig. 3a). Analysis of HCoV-NL63 replication 
showed a 1.5–2 log reduction in virus yield in cells expressing A3C, A3F and A3H, relative to the control sample. 
By contrast, HCoV-NL63 replication was not inhibited in cells expressing GFP, A3A, A3D or A3G (Fig. 3b).
APOBEC3-mediated HCoV-NL63 restriction is associated with cytidine deamination. Because 
HCoV-NL63 infection resulted in upregulation of expression of A3A, A3C, A3D and A3F and A3C, A3F and 
A3H all inhibited HCoV-NL63 replication, we tested whether this inhibition was the result of the catalytic activ-
ity of the APOBECs. Plasmids encoding variants of A3C, A3F and A3H with Glu → Gln substitutions in the 
catalytic site were prepared31 and mRNAs encoding active or inactive proteins were transfected into LLC-Mk2 
cells, which were infected with HCoV-NL63 and cultured prior to visualisation of viral proteins with specific anti-
bodies. The percentages of HCoV-NL63-infected cells were measured by flow cytometry. Wild-type APOBEC3 
proteins resulted in pronounced reductions in HCoV-NL63 infection rates, whereas catalytically inactive proteins 
produced moderate inhibition, with infection rates that were not significantly different from those in controls 
(Fig. 4a). Western blot analysis showed an even expression of all proteins, showing that the inhibitory effect 
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did not result from unequal mRNA translation (Fig. 4b, Supplementary Figure 2). This level of inhibition of 
HCoV-NL63 replication by catalytically inactive proteins required transfection of 3 µg of mRNA, whereas for 
active proteins, inhibition was achieved with transfection of 1 µg of mRNA.
Next, we tested the activity of APOBEC3 proteins in vitro. A DNA template containing several possible sites 
for cytidine deamination (GC-rich domains) was used for in vitro transcription, producing RNA that was incu-
bated with lysates from 293T cells overexpressing A3C protein or GFP. The RNA was then isolated, reverse tran-
scribed, amplified by PCR and sequenced, revealing several C → C/T changes following incubation with A3C 
(but not GFP) cell lysate (Fig. 4c). However, hypermutation did not occur, and no pattern was identified in the 
nucleotide changes.
To examine the progressive accumulation of mutations, we performed a series of virus passages on cells 
expressing A3C, A3F or A3H. Notably, after the first passage, the inhibitory effect of the three APOBECs dimin-
ished, and no decline in virus yield was seen (data not shown). Cell-culture supernatants were collected after 
four passages of HCoV-NL63, and several regions of the viral RNA genome were sequenced. Point mutations 
(G → A or C → T) were identified in the genes encoding the 1ab polyprotein and spike protein in virus passaged 
Figure 1. APOBEC3 gene expression in human airway epithelium (HAE) cell culture. APOBEC3 gene 
expression was analysed in 3D HAE cultures. mRNA levels were evaluated by quantitative RT-PCR. Expression 
was assessed (a) in uninfected HAE cultures, (b) in cultures infected with human coronavirus (HCoV)-NL63 
and (c) in cultures infected with influenza A virus (IVA) strain H3N2. Results are presented as mRNA copy 
number per ml. Infection was performed at 400 TCID50 per ml, for 4 days at 32 °C (for HCoV-NL63) or for 2 
days at 37 °C (for IVA). Each experiment was performed at least three times with clinical material from different 
donors, and with two technical replicates. For comparisons by Student’s t-test, *Indicates P < 0.05; **Indicates 
P < 0.005.
www.nature.com/scientificreports/
4ScIentIFIc REPORts |  (2018) 8:5960  | DOI:10.1038/s41598-018-24448-2
in APOBEC3-expressing cells, but not in wild-type cells. These mutations were not specific to virus collected 
from cells expressing A3C, A3F or A3H, but were also identified in virus passaged in cells expressing A3A, ADE 
or A3G.
To identify whether APOBEC3 protein were capable of inducing hypermutation, we used a recombinant 
GC-rich HCoV-229E virus (ic229E-GC), into which we had introduced silent mutations (either A → G or T → C) 
in the A/T-rich region of nsp6, resulting in a potential ‘hot-spot’ for cytidine deamination. The virus was prop-
agated and titrated to determine the 50% tissue-culture infective dose (TCID50) in naturally permissive Huh-7 
cells. The effectiveness of mRNA transfection in Huh-7 cells was confirmed by detection of green fluorescence 
in cells transfected with GFP mRNA. Huh-7 cells were then transfected with mRNA encoding an APOBEC3 
protein, infected with ic229E-GC at 400 TCID50 per ml and cultured for 5 days. Pronounced inhibition of viral 
infection occurred in cells expressing A3C, A3F or A3H (data not shown). After four passages of ic229E-GC, viral 
RNA was sequenced. No G → A or C → T mutations were identified within the GC-rich region in any of the sam-
ples. However, ic229E-GC passaged in cells expressing A3F protein showed considerable sequence heterogeneity, 
compared with passaged in GFP-positive cells, indicating a possible A3F deaminase activity (Fig. 4d).
APOBEC3 proteins interact with the HCoV-NL63 nucleoprotein. Our results demonstrated that, 
although cytidine deamination was involved in inhibition of coronavirus by APOBEC3 proteins, deaminase 
mutants retained some anti-coronaviral activity, suggesting that an additional mechanism may be involved in 
APOBEC3-mediated coronavirus restriction. We therefore analysed the interactions between APOBEC3 proteins 
(A3C, A3F and A3H) and HCoV-NL63 nucleocapsid protein (HCoV-NL63-N), which is the most abundant 
viral structural protein. Human 293T cells were transiently transfected with plasmid DNA constructs for expres-
sion of individual HA-tagged APOBEC3 proteins (or their catalytically inactive derivatives) or GFP. Cell lysates 
containing the expressed proteins were incubated with purified HCoV-NL63-N, and protein complexes were 
co-immunoprecipitated with anti-HA-tag resin. Western-blot analysis demonstrated co-immunoprecipitation 
of HCoV-NL63-N with A3C, A3F and A3H, whereas no HCoV-NL63-N could be detected in samples incu-
bated with GFP lysate. Notably, the catalytically inactive derivatives of A3C, A3F and A3H also bound to 
HCoV-NL63-N protein (Fig. 5a, Supplementary Figure 3). On the other hand, we could not observe the same 
effect with other APOBEC3 proteins (A3A, A3D and A3G).
Figure 2. HA-tagged APOBEC3 protein expression after DNA or mRNA transfection. (a) 293T cells were 
transiently transfected with plasmid DNA encoding individual APOBEC3 proteins with a C-terminal HA tag. 
APOBEC3 proteins were detected by western blotting using HA-specific antibodies. (b) LLC-Mk2 cells were 
transfected with capped and polyadenylated green fluorescent protein (GFP) mRNA and cultured for 24 h at 
37 °C in an atmosphere containing 5% CO2. Green fluorescence was visualised with a fluorescence microscope. 
BF = bright field. Scale bar = 650 µm. (c) LLC-Mk2 cells were transfected with capped and polyadenylated 
mRNA encoding individual APOBEC3 proteins and cultured for 48 h at 37 °C in an atmosphere containing 5% 
CO2. Protein expression was analysed with flow cytometry using HA-specific antibodies.
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Co-localisation of A3C with HCoV-NL63-N was investigated by co-transfection of LLC-Mk2 cells with 
mRNAs encoding A3C and HCoV-NL63-N, followed by immunofluorescence staining and confocal microscopy. 
The analysis showed several clearly visible foci of co-localisation (Fig. 5b). Calculation of Manders’ coefficient 
gave a value of 0.459, indicating the existence of an interaction between the two proteins.
Discussion
APOBEC3-mediated cytidine deamination has been described as an interim antiviral mechanism. Although 
APOBEC3 proteins were initially shown to primarily modify DNA templates, it has subsequently been demon-
strated that they also use RNA as a substrate. The finding that APOBEC3 deaminases can mutate the HIV 
RNA genome first expanded their possible specificity16. Thereafter, it was shown that A3G impairs the repli-
cation of mumps, measles and respiratory syncytial viruses. This antiviral activity is not an effect of APOBEC3 
Figure 3. Human coronavirus (HCoV)-NL63 infection is inhibited in LLC-Mk2 cells expressing the individual 
APOBEC3 proteins A3C, A3F and A3H. (a) LLC-Mk2 cells were transfected with capped and polyadenylated 
mRNAs encoding individual APOBEC3 proteins. Following 24 h incubation at 37 °C in an atmosphere 
containing 5% CO2, cells were infected with HCoV-NL63 at 400 TCID50 per ml. After a further 120 h incubation 
at 32 °C in an atmosphere containing 5% CO2, development of cytopathic effect (CPE) was assessed by 
observation with an inverted microscope. Scale bar = 170 µm. (b) Cell-culture supernatant was harvested 
at 120 h post-infection, and viral RNA was isolated and reverse transcribed. Virus yield was determined by 
quantitative RT-PCR, and is presented as Log Reduction Value (LRV). Each experiment was performed at least 
three times, with two technical replicates. For comparisons by Student’s t-test, *Indicates P < 0.05.
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Figure 4. Cytidine deamination is relevant for HCoV-NL63 inhibition. (a) LLC-Mk2 cells were transfected 
with capped and polyadenylated mRNA encoding active or catalytically inactive (m) APOBEC3 proteins. 
Following incubation for 24 h at 37 °C in an atmosphere containing 5% CO2, cells were infected with human 
coronavirus (HCoV)-NL63 at 400 TCID50 per ml. After 96 h incubation at 32 °C in an atmosphere containing 
5% CO2, cells were fixed and immunostained for HCoV-NL63 nucleoprotein (N) using specific antibodies. 
The rate of viral infection was analysed by flow cytometry and is presented as the percentage of cells that were 
infected. For comparisons by Student’s t-test, *Indicates P < 0.05. (b) LLC-Mk2 cells were transfected with 
capped and polyadenylated mRNA encoding active or catalytically inactive (m) APOBEC3 proteins. Following 
incubation for 24 h at 37 °C in an atmosphere containing 5% CO2, cells were lysed in RIPA buffer. APOBEC3 
proteins and control GAPDH protein were detected by western blotting using specific antibodies. (c) 293T cell 
lysates enriched in the APOBEC3 protein A3C (lower panel) or green fluorescent protein (GFP) (upper panel) 
were incubated with in vitro-prepared RNA containing a GC-rich sequence for 2 h at 37 °C. The RNA was then 
reverse transcribed, amplified by PCR and sequenced. Experiments were performed at least three times, with 
two technical replicates. (d) Huh-7 cells were transfected with capped and polyadenylated mRNA encoding 
active A3F (lower panel) or GFP (upper panel). Following 24 h incubation at 37 °C in an atmosphere containing 
5% CO2, cells were infected with the recombinant GC-rich HCoV-229E virus (ic229E-GC) at 400 TCID50 per 
ml. After four cycles of virus passage in A3F-positive or GFP-positive cells, viral RNA was isolated, reverse 
transcribed and sequenced across the GC-rich domain.
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enzymatic activity, but is thought to result from the interaction of A3G with viral transcripts18. A3A has been 
shown to act as a mRNA-editing factor in human monocytes and monocyte-derived macrophages17. However, 
APOBEC3-mediated deamination of viral RNA genomes has not previously been demonstrated for viruses that 
do not replicate through DNA intermediates. Here, we investigated the antiviral effects of APOBEC3 proteins on 
human coronaviruses. HCoV-NL63 was selected as the model pathogen because of its prominent bias in nucle-
otide composition (low GC content), suggesting the possible shaping of the genome by cytidine deamination.
We studied the interaction between HCoV and HAE cultures, as an in vitro model of the human airways, 
the primary entry site for human respiratory viruses. mRNA levels of genes encoding A3A, A3C and A3D were 
upregulated in HCoV-NL63-infected cultures. Upregulation of APOBEC3 protein expression was previously 
shown to be dependent on interferon alpha, and it is associated with non-cytolytic clearance of human hepatitis 
B virus in primary hepatocytes32. Cytoplasmic DNA triggers production of type I interferon, leading to massive 
upregulation of APOBEC3A33,34. Here, we investigated the effects of different APOBEC3 proteins, and found that 
expression of A3C, A3F or A3H limits coronavirus infection. Notably, some infectious progeny were produced in 
the presence of these proteins, and serial passaging of virus was possible. Surprisingly, if cells overexpressing A3C, 
A3F or A3H were infected with the progeny virions, no restriction of virus replication occurred. Possible expla-
nations for this effect are that the first viral passage results in selection of viral subspecies that are not affected by 
APOBEC3 activities, or that viral passage activates a viral factor or mechanism that can counteract APOBEC3 
activities.
Serial passage of HCoV in APOBEC3-expressing cells did not result in hypermutation in progeny viruses. It 
is possible that HCoV-NL63 has reached a maximum level of AT content, so that new C → T or G → A changes 
in the genome result in a drastic drop in viral infectivity. However, incubation of an RNA transcript containing 
potential deaminase hot-spots17 with A3C-enriched cell lysates did not result in hypermutation.
The lack of hypermutation might have resulted from limited accessibility of the template or instability of 
A3C in the lysate. We were not able to develop a HCoV-NL63 molecular clone containing GC-rich elements, 
most likely because of low stability of the reverse genetics system for this virus (data not shown). We therefore 
developed a HCoV-229E clone containing a GC-rich region35,36. Replication of this virus was inhibited in cells 
expressing A3C, A3F or A3H, but no mutations were observed in the modified region. The lack of observed 
hypermutation may result from proofreading and repair of the coronavirus RNA genome37, and suggests that 
inhibition of coronaviral replication by APOBEC3 proteins does not result from deamination of viral RNA.
Figure 5. APOBEC3 proteins interact with human coronavirus (HCoV)-NL63 nucleoprotein (N). (a) 293T 
cell lysates enriched in active APOBEC3 proteins (A3C, A3F or A3H) or their catalytically inactive derivatives 
(mA3C, mA3F or mA3H) were incubated with purified HCoV-NL63 N (produced in Escherichia coli)39 for 
1 h at 37 °C. Subsequently, agarose spheres coated with anti-HA antibodies were added, and proteins were 
co-precipitated using spin columns. Samples were separated by electrophoresis and transferred onto PVDF 
membrane, and HCoV-NL63 N and HA-tagged APOBEC3 proteins were detected with specific antibodies. 
PC = positive control protein. (b) LLC-Mk2 cells were transfected with capped and polyadenylated mRNA 
encoding HCoV-NL63 N (Ctrl NL63 N), A3C (Ctrl A3C) or both transcripts (NL63 N + A3C), and incubated 
for 72 h at 37 °C. Cells were then fixed and immunostained for A3C (red), HCoV-NL63 N (green) and nuclei 
(blue). Co-localisation of A3C with HCoV-NL63-N was determined by confocal microscopy and marked with 
arrows. M, Manders’ coefficient (A3C overlapping with the virus). A representative image is shown.
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It was previously shown that, for some RNA viruses, APOBEC-mediated inhibition is deamination-independent. 
In our system, catalytically inactive A3C, A3F and A3H proteins only had marginal inhibitory effect on virus 
replication. We suggest that APOBEC3 proteins may affect coronavirus replication by two mechanisms: first, 
by deamination of yet unidentified cellular targets or deamination of single sites in the coronaviral genome; and 
second, by direct, non-catalytic interaction with viral RNA and/or proteins. APOBEC proteins may interact with 
the coronaviral N protein, which is an essential structural protein for formation of the viral ribonucleocapsid, and 
which also has a role in virus replication38–42. Our results demonstrated that all APOBEC3 proteins with inhibi-
tory activity bound to the N protein. The direct, editing-independent mechanism by which APOBEC3 proteins 
inhibit HCoV-NL63 replication is still to be elucidated, but it is possible that interaction with the N protein inter-
feres with virus replication and progeny production.
In conclusion, our results show that three APOBEC3 proteins (A3C, A3F and A3H) inhibit coronaviral repli-
cation. The molecular mechanism of deaminase-dependent inhibition of coronavirus replication remains elusive 
and may depend on deamination of single sites in the coronaviral genome, or in a cellular target or targets. Passage 
of HCoV-NL63 in cells expressing APOBEC3 proteins results in virus that is resistant to APOBEC-mediated 
inhibition, possibly indicating the presence of an unidentified factor that counteracts APOBEC3 activity. The 
deaminase-independent component of viral inhibition may result from interaction between viral N protein and 
APOBEC3 proteins.
Methods
Cell culture. LLC-Mk2 cells (Macaca mulatta epithelial kidney cells; ATCC: CCL-7) were cultured in H/E 
MEM (Hanks’ MEM: Earle’s MEM, 2:1 ratio; Thermo Fisher Scientific, Poland) with 3% fetal bovine serum 
(heat-inactivated; Thermo Fisher Scientific, Poland) and antibiotics: penicillin (100 U/ml), streptomycin (100 μg/
ml), and ciprofloxacin (5 μg/ml). Human hepatocellular carcinoma Huh-7 (kindly provided by dr Lia van 
der Hoek, UvA, The Netherlands) and 293T (ATCC: CRL-3216; kidney epithelial) cell lines were cultured in 
Dulbecco’s MEM (Thermo Fisher Scientific, Poland) with 10% fetal bovine serum (heat-inactivated; Thermo 
Fisher Scientific, Poland) and antibiotics: penicillin (100 U/ml), streptomycin (100 μg/ml), and ciprofloxacin 
(5 μg/ml). Cells were maintained at 37 °C under 5% CO2.
Human airway epithelium (HAE) cultures. Human epithelial cells were isolated from conductive air-
ways resected from transplant patients. The study was approved by the Bioethical Committee of the Medical 
University of Silesia in Katowice, Poland (approval no: KNW/0022/KB1/17/10 dated on 16.02.2010). A written 
informed consent was obtained from all patients. Tissues were procured at the Silesian Center for Heart Diseases, 
Zabrze, Poland. No organs/tissues were procured from prisoners. Cells were dislodged by protease treatment, and 
later mechanically detached from the connective tissue. Resulting primary cells were first cultured in selective 
media to proliferate. Further, cells were trypsinised and transferred onto permeable Transwell insert supports 
(φ = 6.5). Cell differentiation was stimulated by media additives and removal of media from the apical side. In 
such a manner cells were cultured for 6–8 weeks to form well-differentiated, pseudostratified mucociliary epithe-
lium43. All experiments were performed in accordance with relevant guidelines and regulations.
For the virus infection, HAE cultures were washed thrice with 100 μl of 1 × PBS, following inoculation with 
HCoV-NL63 (isolate Amsterdam 1) or influenza A virus (IVA, strain H3N2) or mock (cell lysate). After 2 h incu-
bation at 32° (for HCoV-NL63) or 37 °C (for IVA) unbound virions were removed by washing with 100 μl of 
1 × PBS and HAE cultures were cultured at an air - liquid interphase until the end of the experiment.
Virus preparation and titration. The stock of HCoV-NL63 (isolate Amsterdam 1) was prepared using 
LLC-Mk2 cells. Six days post-infection (p.i.) infected cells were lysed by freeze-thawing and the resulting super-
natant was stored at −80 °C. Mock sample was prepared in the same manner, from non-infected cells. Virus yield 
was determined according to the method described by Reed and Muench44. Briefly, cells infected with serially 
diluted virus were incubated at 32 °C for 6 days and the appearance of cytopathic effect (CPE) was monitored.
Isolation of nucleic acids and reverse transcription (RT). Viral DNA/RNA Kit (A&A Biotechnology, 
Poland) was used for nucleic acid isolation from cell culture supernatants, according to the manufacturer’s 
instructions. Cellular RNA was isolated using Fenozol reagent (A&A Biotechnology, Poland), followed by DNase 
I treatment (Thermo Fisher Scientific, Poland). cDNA samples were prepared with a High Capacity cDNA 
Reverse Transcription Kit (Thermo Fisher Scientific, Poland), according to the manufacturer’s instructions.
Preparation of GC-rich infectious clone 299E virus mutant. Recombinant HCoV-229E containing a 
GC-rich region was generated using the vaccinia virus-based reverse genetic system as described previously36,45. 
In short, vaccinia virus containing the full-length HCoV-229E cDNA in which an Escherichia coli guanine phos-
phoribosyltransferase (GPT) was inserted between HCoV-229E 10098 and 10930 nucleotides was used to recom-
bine with a plasmid containing HCoV-229E 9398–11580 nucleotides with a number of silent mutations (GC-rich 
region)46. The resulting vaccinia virus was used to rescue the mutant HCoV-229E, as described previously36,45. 
Plasmid DNA, recombinant vaccinia virus and recombinant HCoV-229E identities were confirmed by sequencing.
quantitative PCR (qPCR). RNA yields were assessed using real-time PCR (7500 Fast Real-Time PCR; Life 
Technologies, Poland). HCoV-NL63 cDNA was amplified in a reaction mixture containing 1 × TaqMan Universal 
PCR Master Mix (Thermo Fisher Scientific, Poland), in the presence of FAM/TAMRA (6-carboxyfluorescein/6-
carboxytetramethylrhodamine) probe (100 nM specific) and primers (450 nM each)47. Reaction was carried out 
according to the scheme: 2 min at 50 °C and 10 min at 92 °C, followed by 40 cycles of 15 sec at 92 °C and 1 min 
at 60 °C. Cellular cDNA was amplified in a reaction mixture containing 1 × SYBRGreen Ready PCR Master Mix 
(Sigma-Aldrich, Poland) in the presence of primers (500 nM each). TATA-box binding protein gene (TBP) was 
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used as a household gene control and Rox was used as the reference dye. Primer sequences are provided in 
Table 1. Reaction was carried out according to the scheme: 10 min at 50 °C and 5 min at 95 °C, followed by 40 
cycles of 30 sec at 95 °C, 30 sec at 56 °C and 45 sec at 75 °C. In order to assess the copy number for each gene, DNA 
standards were prepared, as described before47.
Flow cytometry. LLC-Mk2 cells cultured in 6-well plate format (TPP) were washed with sterile 1 × PBS, 
trypsinised, fixed with 4% formaldehyde, permeabilised with 0.1% Triton X-100 in 1 × PBS and incubated for 1 h 
with blocking buffer (10% BSA in 1 × PBS with 0.5% Tween 20).
To visualise HA-tagged APOBEC3 proteins after mRNA transfection, cells were incubated for 2 h at room 
temperature with mouse anti-HA-tag antibody (1 μg/ml, Antibodies-online, Germany) in 1 × PBS with 3% BSA 
and 0.5% Tween 20, followed by 1 h incubation with Alexa Fluor 488-labeled goat anti-mouse antibody (2.5 μg/
ml, Molecular Probes, Poland).
To evaluate HCoV-NL63 infection using flow cytometry, cells were incubated for 2 h at room temperature 
with mouse anti-HCoV-NL63-N antibody (1 μg/ml, Ingenansa, Spain) in 1 × PBS with 3% BSA and 0.5% Tween 
20, followed by 1 h incubation with Alexa Fluor 488-labeled goat anti-mouse antibody (2.5 μg/ml, Molecular 
Probes, Poland). Cells were then washed, re-suspended in 1 × PBS and analysed with FACS Calibur (Becton 
Dickinson, USA) using Cell Quest software.
APOBEC3 expression constructs and site-directed mutagenesis. Sequence verified, C-terminal 
HA-tagged pTracer CMV2 plasmids (Thermo Fisher Scientific, Poland) encoding human A3A (GeneBank acces-
sion number (GB) NM_145699), A3C (GB: NM_014508), A3DE (GB: NM_152426), A3F (GB: NM_145298), 
APOBEC3G (GB: NM_021822) and A3H (GB: NM_181773) were prepared. Catalytic mutants of A3C (A3C_
E68Q = mA3C), A3F (A3F_E251Q = mA3F) and A3H (A3H_E56Q = mA3H) were prepared using Quick 
Change mutagenesis with Phusion polymerase (Thermo Fisher Scientific, Poland)48. Sequences of oligonucleo-
tides used are listed in Table 2.
Design of “hot-spot” RNA. Plasmid construct containing several GC-rich domains was ordered at 
GeneArt Gene Synthesis (Thermo Fisher Scientific, Germany). The region was sequenced with primers 5′-CTG 
TGG AAA ACC TTT GGC ATC-3′ and 5′-CTG TGG AAA ACC TTT GGC ATC-3′. The plasmid was amplified 
in E. coli TOP10 strain and further used as a template in in vitro transcription reaction using T7 promoter, as 
described below.
Preparation of mRNA molecules for transfection. APOBEC3 plasmids described above were used as 
templates for amplification of APOBEC3 genes with forward primer containing the T7 promoter region (5′-TCG 
GCC TCG TAG GCC TAA TAC GAC TCA CTA TAG GGA GAC TGA GAG AAC CCA CTG CTT AC-3′) 
and specific reverse primer (listed in Table 2, 500 nM each). Reaction was carried out with Phusion polymerase 
(Thermo Fisher Scientific, Poland), according to the manufacturer’s instructions. DNA templates were purified 
using GeneJET PCR Purification Kit (Thermo Fisher Scientific, Poland) and further used for in vitro transcrip-
tion with T7 RiboMAX Express Large Scale RNA Production System and Ribo m7G Cap Analog (Promega, 
Poland). Resulting RNA was precipitated with LiCl, purified with 70% ethanol and polyadenylated using Poly(A) 
Target Primer Primer sequence (5′–3′)
HCoV-NL63
Sense CTG TGG AAA ACC TTT GGC ATC
Antisense CTG TGG AAA ACC TTT GGC ATC
Probe ATG TTA TTC AGT GCT TTG GTC CTC GTG AT
A3A
Sense TGG TTC CTT CTT TGC AGT TGG ACC
Antisense GCA GCA TTT GCA GTG CCT CCT TAT
A3B
Sense AGC ACA TGG GCT TTC TAT GCA ACG
Antisense AGG AGA TGA ACC AAG TGA CCC TGT
A3C
Sense AAC GAA ACT TGG CTG TGC TTC ACC
Antisense AGA CAG TAT GTC GTC GCA GAA CCA
A3D
Sense AGG CAG GAG GTG TAT TTC CGG TTT
Antisense GGT GCT CAG CCA AGA ATT TGG TCA
A3F
Sense TCC GTG GAG ATC ATG GGC TAC AAA
Antisense TGC AGC TTG CTG TCC AGG AAT AGA
A3G
Sense GCT GTG CCC AGG AAA TGG CTA AAT
Antisense ACA AAG GTG TCC CAG CAG TGC TTA
A3H
Sense TGA CTT CAT CAA GGC TCA CGA CCA
Antisense GTC AGC AAA CTT TGG GAA GCC CAT
TBP
Sense CCC ATG ACT CCC ATG ACC
Antisense TTT ACA ACC AAG ATT CAC TGT GG
Table 1. Primers and probes used for a RT-qPCR.
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Tailing Kit (Thermo Fisher Scientific, Poland), according to the manufacturer’s instructions. RNA was then pre-
cipitated with lithium chloride (Thermo Fisher Scientific, Poland) and its concentration was assessed using a 
spectrophotometer.
Transfection of plasmid DNA and mRNA. 293T cells were seeded on 10 cm2 dishes, cultured for 24 h at 
37 °C with 5% CO2 and transfected with 8 µg of plasmid per dish using polyethylenimine (Sigma-Aldrich, Poland). 
LLC-Mk2 and Huh-7 cells were seeded on 6-wells plates (TPP, Switzerland), cultured for 24 h at 37 °C with 5% 
CO2 and transfected with 3 µg mRNA per well (transcripts encoding APOBEC3 proteins or control GFP) using 
TransIT mRNA Transfection Reagent (Mirus, USA). Efficiency of transfection was assessed 24 h post-transfection 
in GFP-transfected cells using EVOS fluorescent microscope (Thermo Fisher Scientific, Poland).
Western blot analysis. Cells were trypsinised, centrifuged and resuspended in RIPA buffer (50 mM Tris, 
150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, pH 7.5) followed by lysis in RIPA buffer 
for 30 min on ice. Subsequently, samples were centrifuged (10 min at 12,000 × g) and the pelleted cell debris 
was discarded. Resulting supernatants were mixed with sample buffer (0.5 M Tris pH 6.8, 10% SDS, 50 mg/ml 
DTT), boiled for 5 min, cooled on ice, and separated on 10% polyacrylamide gels alongside dual color Page Ruler 
Pre-stained Protein size markers (Thermo Fisher Scientific, Poland). The separated proteins were then trans-
ferred onto a Westran S PVDF membrane (GE Healthcare, Poland) by wet blotting (Bio-Rad, Poland) for 1 h, 100 
Volts in transfer buffer: 25 mM Tris, 192 mM glycine, 20% methanol at 4 °C. The membranes were then blocked 
by overnight incubation at 4 °C in TBS-Tween (0.1%) buffer supplemented with 5% skimmed milk (BioShop, 
Canada). A rabbit anti-HA Taq antibody (1 μg/ml; Antibodies-online, USA) and horseradish peroxidase-labeled 
goat anti-rabbit IgG (0.35 μg/ml; Sigma-Aldrich, Poland) were used to detect the HA-tagged APOBEC3 pro-
teins in cell lysates. Mouse anti-HCoV-NL63-N protein antibody (500 ng/ml; Ingenansa, Spain) and horserad-
ish peroxidase-labeled rabbit anti-mouse IgG (65 ng/ml; Dako, Denmark) were used to detect the HCoV-NL63 
nucleocapsid protein. A rabbit anti-GAPDH antibody (1:5000 dilution; Cell Signalling Technology, Poland) and 
horseradish peroxidase-labeled goat anti-rabbit IgG (0.35 μg/ml; Sigma-Aldrich, Poland) were used to detect 
the GAPDH in cell lysates. All antibodies were diluted in 1% skimmed milk/TBS-Tween (0.1%). The signal was 
developed using the Immobilon Western Chemiluminescent HRP Substrate (Millipore, USA) and visualised by 
exposing the membrane to an X-ray film (Kodak, Poland).
Nucleocapsid protein binding analysis. APOBEC3-expressing and control 293T cells were harvested 
3 days post transfection in deaminase activity buffer, containing 0.2% Surfact-Amps NP-40 (Sigma-Aldrich, 
Poland), 30 mM 4-(2-hydroxyethyl)-1-piperazine-ethane-sulfonic acid (HEPES; pH 7.5), 100 mM KCl, 25 mM 
NaCl, 1.5 mM MgCl2, 1 mM DTT, 1 × Halt protease and phosphatase inhibitor cocktail, and 10% glycerol17. 
Samples were centrifuged (10 min at 12,000 × g), pelleted cell debris was discarded and resulting supernatants 
were stored at −80 °C. HCoV-NL63 N protein was prepared as described previously39. Cell lysates were incubated 
Target Primer Primer sequence (5′–3′)
Oligonucleotides used for plasmids construction
A3A
Sense ACG CGA ATT CCA CCA TGG AAG CCA GCC CAG CAT CCG G
Antisense GAC TGC GGC CGC CTA TCA AGC GTA ATC TGG AAC ATC GTA TGG GTA GTT TCC CTG ATT CTG GAG AA
A3C
Sense ACG CGA ATT CCA CCA TGA ATC CAC AGA TCA GAA ACC CGA TG
Antisense GAC TGC GGC CGC CTA TCA AGC GTA ATC TGG AAC ATC GTA TGG GTA CTG GAG ACT CTC CCG TAG CC
A3D
Sense ACG CGA ATT CCA CCA TGA ATC CAC AGA TCA GAA ATC C
Antisense GAC TGC GGC CGC CTA TCA AGC GTA ATC TGG AAC ATC GTA TGG GTA CTG GAG AAT CTC CCG TAG CC
A3F
Sense ACG CGG TAC CCA CCA TGA AGC CTC ACT TCA GAA ACA C
Antisense GAC TGC GGC CGC CTA TCA AGC GTA ATC TGG AAC ATC GTA TGG GTA CTC GAG AAT CTC CTG CAG CT
A3G
Sense ACG CGG TAC CCA CCA TGA AGC CTC ACT TCA GAA ACA C
Antisense GAC TGC GGC CGC CTA TCA AGCG TAA TCT GGA ACA TCG TAT GGG TAG TTT TCC TGA TTC TGG AGA A
A3H
Sense ACG CGA ATT CCA CCA TGG CTC TGT TAA CAG CCG AAA C
Antisense GAC TGC GGC CGC CTA TCA AGC GTA ATC TGG AAC ATC GTA TGG GTA GAC CTC AGC ATC ACAC AAT A
Oligonucleotides used for Quick Change mutagenesis
mA3C
Sense GTC ATG CAC AAA GGT GCT TCC TCT CTT G
Antisense GCA CCT TTG TGC ATG ACA ATG GGT CTC
mA3F
Sense GTC ATG CAC AAA GGT GCT TCC TCT CTT G
Antisense GCA CCT TTG TGC ATG ACA ATG GGT CTC
mA3H
Sense GCC ATG CAC AAA TTT GCT TTA TTA ACG
Antisense GCA AAT TTG TGC ATG GCA CTT TTT CTT G
Table 2. Primers used for generation of expression constructs and deaminase mutants.
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for 1 h at 37 °C with the purified N protein in 1 × activity buffer, containing 100 mM KCl, 10 mM HEPES (pH 7.4), 
100 µM ZnCl2, 1 mM DTT and 1 mM EDTA17. Subsequently, 15 µl of agarose spheres coated with anti-HA anti-
bodies (Pierce, Poland) was added and samples were loaded onto co-immunoprecipitation columns. After over-
night incubation at 4 °C on a rotary shaker, proteins were eluted, according to the manufacturer’s instructions.
Analysis of HCoV-NL63 co-localisation with APOBEC3C. LLC-Mk2 cells were seeded on 6-wells 
plates and cultured for 24 h at 37 °C with 5% CO2. 1.5 μg of HCoV-NL63 N mRNA and 1.5 μg of A3C mRNA 
was co-transfected using the mRNA-In reagent (AMS Biotechnology, United Kingdom). After 72 h incubation 
at 37 °C with 5% CO2, cells were fixed with 4% formaldehyde, permeabilised with 0.1% Triton X-100 in 1 × PBS 
and incubated overnight at 4 °C with 10% BSA in 1 × PBS with 0.5% Tween 20. To visualise HCoV-NL63 N mol-
ecules, cells were incubated for 2 h at room temperature with rabbit anti-HCoV-NL63-N serum (1:100 dilution, 
kindly provided by dr Lia van der Hoek, UvA, The Netherlands) in 1 × PBS with 3% BSA and 0.5% Tween 20, 
followed by 1 h incubation with Atto 488-labeled goat anti-rabbit IgG (5 μg/ml; Sigma-Aldrich, Poland). To detect 
HA-tagged A3C protein cells were incubated for 2 h at room temperature with mouse Alexa Fluor 647-labeled 
anti-HA-tag antibody (10 μg/ml; Thermo Fisher Scientific; Poland) in 1 × PBS with 3% BSA and 0.5% Tween 
20. Nuclear DNA was stained with DAPI (0.1 μg/ml; Sigma-Aldrich, Poland). Immunostained cultures were 
mounted on glass slides with ProLong Gold antifade medium (Thermo Fisher Scientific; Poland). Fluorescent 
images were acquired under a Zeiss LSM 710 confocal microscope (Carl Zeiss Microscopy GmbH). Images 
were acquired using ZEN 2012 SP1 software (Carl Zeiss Microscopy GmbH) and processed using ImageJ 1.47 v 
(National Institutes of Health, Bethesda, Maryland, USA).
Statistical analysis. All the experiments were performed in triplicate and the results are presented as 
mean ± SD. Student’s t-test was used to determine significance of the obtained results. P values < 0.05 were con-
sidered significant.
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